News Novo Nordisk files Wegovy product that claimed rapid voucher Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News Disappointment as Novo's oral GLP-1 fails in Alzheimer's GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.
News Lilly becomes first $1trn+ pharma company Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group populated mainly by tech giants.
News Novo Nordisk cuts Wegovy price ahead of TrumpRx launch Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.
News Novo Nordisk fights back with oral GLP-1 data in obesity Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.
News Novo Nordisk cuts guidance again on weaker GLP-1 growth Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
